Kornimate/medical-research-clean huggingface dataset:
awareness, information, and resources for lung cancer screening program for community-partnered lung cancer screening

Conditions: Lung Carcinoma

Summary: this trial investigates an educational program called awareness, information, and resources for lung cancer screening program in improving knowledge about lung cancer screening in medically underserved communities. this program aims to educate and remove barriers to lung cancer screening among medically underserved community members who are eligible for lung cancer screening, and to improve access to evidence-based screening guidelines for early detection for lung cancer in the western new york area.

primary objectives: i. collaborate with community organizations and leaders to leverage community-based assets to disseminate education about lung cancer screening. ii. reach medically underserved, high risk community members. iii. enhance lung cancer screening knowledge among medically underserved, high risk community members. iv. navigate screening-eligible community members to lung cancer screening. outline: participants complete the roswell awareness, information and resources for lung cancer screening (air) program over 45 minutes and then receive the high-risk lung cancer tip sheet.

Eligibility criteria:
inclusion criteria: * members of all races and ethnic groups are eligible for this study exclusion criteria: * adults unable to consent
acetazolamide for the prevention of post operative csf leak

Conditions: Cerebrospinal Fluid Leak

Summary: the purpose of this research is to test the use of acetazolamide in preventing post-operative cerebrospinal fluid leak in patients having endoscopic skull base surgery (it is a surgery performed through the nose and sinus).


Eligibility criteria:
inclusion criteria: * elective transsphenoidal resection of a tumor expected to result in an intraoperative high flow csf leak; such tumors include craniopharyngioma, meningioma, and rathke cleft cyst. * elective transsphenoidal resection of a pituitary adenoma, with bmi \>25, or with observed low or high flow csf leak during surgery, conferring an elevated risk of postoperative csf leak. * patients who voluntarily sign informed consent * male subjects and female subjects of childbearing potential and at risk for pregnancy must agree to use a highly effective method of contraception during study treatment and for at least 1 month after stopping study treatment. male subjects should refrain from donating semen during treatment and 1 month after stopping treatment. exclusion criteria: * adults unable to consent * individuals who are not yet adults (infants, children, teenagers) * pregnant women * prisoners * patients with prior adverse reactions to acetazolamide or who are taking aspirin concomitantly (which may increase the risk of adverse reactions to acetazolamide) * patients with moderate to severe chronic obstructive pulmonary disease (which may increase the risk of adverse effects of acetazolamide) * acetazolamide therapy is contraindicated in situations in which sodium and/or potassium blood serum levels are depressed, in cases of marked kidney and liver disease or dysfunction, in suprarenal gland failure, and in hyperchloremic acidosis. * it is contraindicated in patients with cirrhosis because of the risk of development of hepatic encephalopathy * sulfonamide allergy * pregnant females, breastfeeding females, and males and females of childbearing potential who are unwilling or unable to use a highly effective method of contraception
assessment of the stroke rehabilitation assessment of movement as a clinical tool

Conditions: Stroke

Summary: the stroke rehabilitation assessment of movement (stream) is a relatively new measurement tool, which measures specific movement deficits (impairments) caused by a stroke. the stream is used to evaluate recovery of voluntary movement and basic mobility following the onset of a stroke. several important clinical measurement properties of the stream remain to be explored, including its ability to measure impairments and clinical change in acute rehabilitation patients in the usa. we hypothesize that the stream will be able to detect and quantify a statistically significant change in the motor abilities of stroke patients from admission to discharge. an additional aim of the study is to compare the stream with two accepted and widely used clinical measures of function and disability, the stroke impact scale (sis)and the functional independence measure (fim). by linking movement deficits that are commonly assessed by physical therapists with measures of function and disability, the impact of the movement deficits can be understood.


Eligibility criteria:
inclusion criteria: * comprehension of english * age 18 and older * first-time stroke * receiving in-patient rehabilitation at the rusk institute of rehabilitation medicine, new york, ny exclusion criteria: * hemorrhagic stroke * brain stem or cerebellar infarct * other pre-existing neurologic conditions

Keywords: function disability
a study of tocilizumab in combination with dmard therapy in patients with active rheumatoid arthritis.

Conditions: Rheumatoid Arthritis

Summary: this 2 arm study will compare the safety and efficacy, with regard to reduction of signs and symptoms, of tocilizumab versus placebo, both in combination with dmards, in patients with active rheumatoid arthritis who currently have an inadequate response to dmard therapy. patients will be randomized 2:1 to receive tocilizumab 8mg/kg iv or placebo iv every 4 weeks, in conjunction with stable dmard therapy. the anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.


Eligibility criteria:
inclusion criteria: * adult patients, 18-70 years of age; * rheumatoid arthritis for \>= 6 months; * receiving permitted dmards, at a stable dose, for \>= 8 weeks prior to baseline; * current inadequate clinical response to dmards. exclusion criteria: * major surgery, including joint surgery, within 8 weeks before entering study, or planned major surgery within 6 months following randomization; * rheumatic autoimmune disease or inflammatory joint disease other than rheumatoid arthritis; * unsuccessful treatment with an anti-tnf agent; * previous treatment with tocilizumab.
benefit of daa therapy in hcv monoinfected and hiv-hcv coinfected patients with mixed cryoglobulinemia

Conditions: Hepatitis C, Chronic; Mixed Cryoglobulinemia

Summary: mixed cryoglobulinemia (mc) is common in patients with chronic hepatitis c virus (hcv) infection. direct-acting antiviral (daa) regimens are today very effective with sustained virological response rates (svr12) above 90%. the objective of this study was to investigate the impact of daa therapy on cryoglobulin clearance in patients with hcv-associated mc.

we focused on hcv patients with or without hiv with mc who had at least one cryoglobulin level assessment before and after daa therapy and investigated the impact of daa therapy on cryoglobulin clearance.

Eligibility criteria:
inclusion criteria: * hepatitis c virus (hcv) infected patients * symptomatic or asymptomatic mixed cryoglobulinemia * coinfected or not with hiv * treated by direct-acting antiviral (daa) treatment * at least one cryoglobulin measurement before and after daa exclusion criteria: -
evaluation of the lung capillary blood volume in children with sickle cell disease

Conditions: Sickle Cell Disease

Summary: sickle cell disease (scd) is the most common inherited disease of the world affecting african and caribbean populations. scd is caused by the homozygous inheritance of the gene for sickle hemoglobin (hbs). most patients with scd develop abnormal pulmonary function characterized by airway obstruction, restrictive lung disease, abnormal diffusing capacity, hypoxemia and pulmonary hypertension in healthy subjects, lung capillary blood volume (qc) and membrane diffusing capacity (dm) can be accurately measured by the nitric oxide-carbon monoxide (no-co) method. we propose to study, for the first time, lung capillary blood volume and alveolar membrane diffusing capacity, using the no-co method, in children with scd aged of at least 6 years early determination of lung function and pulmonary circulation in children with scd is very important, not only for the understanding of physiopathologic mechanisms of the disease but also for a better therapeutic management of these children.

we propose to study, for the first time, lung capillary blood volume and alveolar membrane diffusing capacity, using the no-co method, in children with scd aged of at least 6 years. we will compare lung function and measurement of qc and dm in 2 groups of 120 subjects, one group of scd children, and the other of normal children matched on age and ethnic origin. measurement of lung capillary blood will be measured twice, to assess short term reproducibility. the measurement will be done in sitting position and lying down for one part of subjects, and at rest and during a moderate rectangular exercise for the other part of subjects. these different tests are designed to assess the physiological adaptation of pulmonary circulation in these two populations of children. combined with complete lung function measurements, echocardiographic assessment of pulmonary hemodynamics, and measurement of exhaled nitric oxide, these evaluations will lead to a better understanding of pathophysiology of lung injury in scd. the study will be completes at robert debré hospital, in close collaboration with sickle cell disease center and physiology department. children will be included after informed consent signed, as legally prescribed.

Eligibility criteria:
inclusion criteria: * children between 6 and 18 years * sickle cell disease( ss,sc, sbeta o, sdpunjab) and control without sickle cell disease * social insurance * signed informed consent exclusion criteria: * respiratory disease other tha asthma * cardiac disease * encephalopathy * g6pd deficiency * consent not signed

Keywords: sickle cell disease; lung capillary blood volume; children
impact of acthar on everyday life of participants with severe keratitis

Conditions: Keratitis

Summary: we will need about 36 participants for this study. volunteers might be able to participate if: * they have bad noninfectious keratitis * early treatments failed or were not well tolerated participants will be in the study for about 22 weeks: * 4 weeks for tests to see if the study might be good for them * 12 weeks of treatment with acthar gel * 4 weeks to wean off acthar gel and follow-up with the doctor


Eligibility criteria:
inclusion criteria: * has severe or recalcitrant keratitis * did not respond to, or tolerate, treatment with topical cyclosporine, lifitegrast, or any immunosuppressant to treat keratitis * if able to reproduce, agrees to use 2 forms of effective contraception with a partner of the opposite sex for the duration of the study (through visit 6) * has normal eyelids, and protocol-defined physical and medical eye attributes * agrees to avoid wearing contact lenses during the trial exclusion criteria: * is pregnant or breast-feeding * is defined as vulnerable, or is employed by, or related to anyone involved in the study * has a medical condition or history that might, per protocol or in the opinion of the investigator, compromise the participant's safety or study analysis

Keywords: severe or recalcitrant keratitis
melatonin agonist effects of tasimelteon versus placebo in patients with major depressive disorder

Conditions: Major Depressive Disorder

Summary: the purpose of this study is to evaluate the safety and efficacy of an 8-week double-masked treatment of tasimelteon or placebo in male and female subjects with major depressive disorder.

this is a randomized, parallel, double-masked, placebo-controlled, multicenter outpatient study comparing tasimelteon with placebo in the treatment of subjects with major depressive disorder (mdd). the study has three phases: the pre-randomization phase, the randomization phase, and an open-label extension phase. the pre-randomization phase comprises a screening visit where subject's initial eligibility will be evaluated. the randomization phase is comprised of an 8-week double-masked segment. subjects meeting all entry criteria for the study will enter the randomization phase. during this phase, subjects will be asked to take either 20 mg tasimelteon or placebo for 8 weeks in a double-masked fashion. at the end of the 8-week double-masked phase, those subjects who completed the 8-week treatment phase will be offered to enroll into a 52-week open-label extension where each subject will receive daily doses of 20 mg tasimelteon.

Eligibility criteria:
inclusion criteria: * subjects with diagnosis of mdd, single or recurrent episode, according to dsm-iv tr criteria; * current episode ≥4 weeks and ≤1 year; * cgi-severity score ≥4 at screening and baseline. exclusion criteria: * lifetime history of bipolar disorder (i or ii), schizophrenia, schizoaffective disorder, eating disorder, or obsessive-compulsive disorder; * any other current axis i (except general anxiety disorder as long as it is not considered the primary disorder) or axis ii disorder; * a positive test for drugs of abuse at the screening visit and/or history of drug or alcohol abuse/dependence as defined in dsm-iv tr, diagnostic criteria for drug and alcohol abuse and dependence, within the past 12 months; * formal psychotherapy within 3 months of the screening visit. general supportive psychotherapy is acceptable; * participation in a previous tasimelteon trial. other protocol-defined inclusion/exclusion criteria may apply

Keywords: tasimelteon major depressive disorder mdd depression
study in healthy adults to determine the effect that food has on the absorption and delivery of the drug cystagon™

Conditions: Cystinosis; Nephropathic Cystinosis

Summary: in order to meet fda standards of safety and efficacy reporting for most new drugs, food-effect bioavailability (the impact that the presence of food in the digestive tract has on the rate and extent at which a drug is absorbed into the bloodstream and delivered to the site of action) must be collected. cystagon™ is an fda approved drug for the treatment of the rare disease cystinosis that became available in 1994, but there is inadequate knowledge of the food-effect on this drug's bioavailability. this study aims to investigate how food affects the absorption of cystagon™ into the bloodstream of normal healthy adults.


Eligibility criteria:
inclusion criteria: 1. male or female, smoker (no more than 25 cigarettes daily) or non-smoker, 18 years of age and older, with bmi \> 18 and \< 30.0. 2. females of childbearing potential who are sexually active must be willing to use two forms of contraceptive methods throughout the study and for 14days after the last study drug administration. 3. minimum weight of 50 kg. 4. good health, defined as not having history of any chronic illness and not requiring any regular medication/therapy. 5. must swallow tablets on a regular basis. exclusion criteria: 1. evidence of helicobacter pylori infection, presently, or within the last year. 2. subjects with known hypersensitivity to cysteamine. 3. history, currently or within the past 3 months, of the following conditions: * pancreatitis * inflammatory bowel disease * malabsorption * severe liver disease * unstable heart disease, e.g., myocardial infarction, heart failure, arrhythmias. * unstable diabetes mellitus * any bleeding disorder. * zollinger-ellison syndrome * malignant disease 4. subjects whom may be pregnant or have health issues that make it unsafe for them participate, or whose concomitant medical problems preclude them from committing to the study schedule. 5. use of an investigational drug within 30 days (or 90 days for biologics) prior to dosing. 6. use of prescription medication within 14 days prior to the first dosing; 7. use over-the-counter products including natural health products (e.g. food supplements and herbal supplements) within 7 days prior to the first dosing. 8. donation of plasma within 7 days prior to dosing. donation or loss of blood (excluding volume drawn at screening) of 50 ml to 499 ml of blood within 30 days, or more than 499 ml within 56 days prior to dosing. 9. hemoglobin \<13.5 g/dl (males) and \<12.0 g/dl (females) and hematocrit \<41.0% (males) and \<36.0% (females) at screening. 10. breast-feeding subject. 11. immunization with a live attenuated vaccine 1 month prior to dosing or planned vaccination during the course of the study. 12. presence of fever (body temperature \>37.6°c) (e.g. a fever associated with a symptomatic viral or bacterial infection) within 2 weeks prior to dosing. -

Keywords: lysosomal storage diseases metabolic diseases metabolism, inborn errors
sorbent treatment prescriptions pilot study

Conditions: Renal Failure

Summary: this study will compare how well blood of renal failure patients is cleaned with the new 2008 sorbent system using two different dialysate speeds.

the "2008 sorbent system" is a new type of hemodialysis machine that requires only about 2 gallons of dialysate for a treatment because it can turn used dialysate into fresh dialysate again by filtering it through a special cleaning cartridge (called a "sorbent"). this new machine is approved by the u.s. food and drug administration to clean the blood of patients whose kidneys have failed. this study will compare the degree of blood cleansing achieved with the new 2008 sorbent system using two different speeds at which the dialysate runs through the dialysis machine. this will tell us if the faster speed really does provide better cleaning (and how much) with this new machine. how well the blood of a patient is cleaned by this procedure is determined by several factors. for example, longer treatment times generally provide better blood cleansing. higher speeds at which the cleaning fluid runs through the artificial kidney do, too. since the 2008 sorbent system is a new machine (and in some ways different from standard hemodialysis machines), other aspects may be different, too, between the 2008 sorbent system and regular hemodialysis machines. specifically, this study looks at how well this new machine corrects the patients' acid-base status (a common requirement in these patients), what effect the treatment has on inflammation in the patients' blood, how the levels of important substances in the blood are influenced (acetate, sulfate, nitrate, carbon dioxide), and if cleaning fluid in the 2008 sorbent system contains any substances that are not found in the cleaning fluid used by regular hemodialysis machines.

Eligibility criteria:
inclusion criteria: * age \</=18 years * end-stage renal disease (esrd) patient on chronic high-flux hemodialysis for \</= 6 months at time of enrollment * well-functioning fistula, graft or catheter as hemodialysis access, achieving blood flow rates of \>/= 300 ml/min * ability to understand the english language exclusion criteria: * pre-dialysis serum blood urea nitrogen (bun) concentration below 30 mg/dl in the last three months * severe coronary heart disease or heart failure (new york heart association class iv) * active infections * hepatitis b * any other active infection that has required antibiotic treatment in the preceding eight weeks * pre-study lab values of any of the following (in the most recent routine lab work) * sodium - na+ \> 150 mmol/l, na+ \< 132 mmol/l * potassium - k+ \> 6.5 mmol/l, k+ \< 3.5 mmol/l * total calcium - ca \> 12 mg/dl (3 mmol/l), total ca \< 7.2 mg/dl (1.8 mmol/l)
effect of tdcs on upper extremity after strokes

Conditions: Stroke

Summary: the investigators hypothesize that transcranial direct current stimulation (tdcs) can improve upper limb motor recovery in the sub-acute phase of stroke patients. this is a randomized, controlled, double blind, cross-over, multicentre, clinical trial.

the investigators hypothesize that transcranial direct current stimulation (tdcs) can improve upper limb motor recovery in the sub-acute phase of stroke patients. this is a randomized, controlled, double blind, cross-over, multicentre, clinical trial. informed consent was obtained from all participants and procedures were conducted according to the declaration of helsinki. the protocol was approved by the chonbuk national uni. hospital irb, korea. seventy-two stroke patients in the sub-acute phase will be recruited in three centers of neurorehabilitation in republic of korea. patients will be randomly divided to four groups; group1 is anodal stimulation on the lesioned primary motor cortex, group 2 is cathodal stimulation on the non-lesioned primary motor cortex, group 3 is dual stimulation such as anodal stimulation on the lesioned side and cathod stimulation on the non-lesioned side, and group 4 is shame stimulation group. the stimulation will be conducted 2ma for 20 minute a day, 5 days per weeks, totally 2 weeks. fugl-meyer upper motor score will be measured as a primary outcome.

Eligibility criteria:
inclusion criteria: 1. age 20-85 2. unilateral stroke patients 3. inclusion must be in the sub-acute phase defined as within 48hr-4 weeks after stroke 4. patients who have evoked motor potentials on the first dorsal interossei muscles on hemiplegic hand 5. the patient has subscribed the informed consent exclusion criteria: 1. insert a metal object on the head 2. convulsive disorders 3. history of brain diseases other than stroke
prosat - effect of probiotics on satiety

Conditions: Obesity; Appetite Regulation

Summary: the aim of the prosat study is to examine the effects of a probiotic capsule containing one of two doses (low and high dose) of lb. casei on subjective appetite sensation, ad libitum energy intake, and appetite hormone response in a single meal test and to determine whether the acute effects persist after daily supplementation of the probiotic capsule.


Eligibility criteria:
inclusion criteria: * healthy men and women * normal to slight overweight (bmi: 22-28 kg/m2) * 20-45 years of age exclusion criteria: * smoking * daily medicine use (oral contraceptives excluded) * use of pre- and probiotic supplements and foods * blood donation 3 months prior to the study * hb\<8mmol/l * chronic illnesses such as hyperlipidemia, diabetes inflammatory diseases * pregnancy or breastfeeding * elite athletes (\>10 hours hard exercise/week) * vegetarians